Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis

Jing Zhang1 Cancer Center, West China Hospital, Collaborative Innovation Center for Biotherapy;2 Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu

Jinying Li3 The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao Central Hospital, Qingdao, People’s Republic of China

Chenjing Zhu1 Cancer Center, West China Hospital, Collaborative Innovation Center for Biotherapy

Yanlin Song1 Cancer Center, West China Hospital, Collaborative Innovation Center for Biotherapy

Fan Xia1 Cancer Center, West China Hospital, Collaborative Innovation Center for Biotherapy

Xuelei Ma1 Cancer Center, West China Hospital, Collaborative Innovation Center for BiotherapyCorrespondence[email protected]

Pages 3235-3244 | Published online: 15 Nov 2017

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience19872354785 177 1823798106
PubMed Web of Science ®Google Scholar
RossJSSlodkowskaEASymmansWFPusztaiLRavdinPMHortobagyiGNThe HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicineOncologist2009144 320 36819346299
PubMed Web of Science ®Google Scholar
SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med200134411 783 79211248153
PubMed Web of Science ®Google Scholar
ChariRVTargeted cancer therapy: conferring specificity to cytotoxic drugsAcc Chem Res2008411 98 10717705444
PubMed Web of Science ®Google Scholar
Lewis PhillipsGDLiGDuggerDLTargeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateCancer Res20086822 9280 929019010901
PubMed Web of Science ®Google Scholar
JunttilaTTLiGParsonsKPhillipsGLSliwkowskiMXTrastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancerBreast Cancer Res Treat20111282 347 35620730488
PubMed Web of Science ®Google Scholar
VermaSMilesDGianniLTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med201236719 1783 179123020162
PubMed Web of Science ®Google Scholar
KropIEKimSBGonzalez-MartinATrastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialLancet Oncol2014157 689 69924793816
PubMed Web of Science ®Google Scholar
ScheuerWFriessTBurtscherHBossenmaierBEndlJHasmannMStrongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor modelsCancer Res20096924 9330 933619934333
PubMed Web of Science ®Google Scholar
BaselgaJCortesJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med20123662 109 11922149875
PubMed Web of Science ®Google Scholar
SwainSMBaselgaJKimSBPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerN Engl J Med20153728 724 73425693012
PubMed Web of Science ®Google Scholar
PhillipsGDFieldsCTLiGDual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapyClin Cancer Res2014202 456 46824097864
PubMed Web of Science ®Google Scholar
KropIEModiSLoRussoPMPhase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancerBreast Cancer Res2016181 3426979312
PubMed Web of Science ®Google Scholar
MartinMFumoleauPDewarJATrastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa studyAnn Oncol2016277 1249 125627052654
PubMed Web of Science ®Google Scholar
PerezEABarriosCEiermannWTrastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE StudyJ Clin Oncol2017352 141 14828056202
PubMed Web of Science ®Google Scholar
MoherDLiberatiATetzlaffJAltmanDGPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementJ Clin Epidemiol20096210 1006 101219631508
PubMed Web of Science ®Google Scholar
GuptaMWangBCarrothersTJEffects of trastuzumab emtansine (T-DM1) on QT interval and safety of pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast cancerClin Pharmacol Drug Dev201321 11 2427121556
PubMed Web of Science ®Google Scholar
MillerKDDierasVHarbeckNPhase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancerJ Clin Oncol20143214 1437 144424733796
PubMed Web of Science ®Google Scholar
SeidmanADBerryDCirrincioneCRandomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840J Clin Oncol20082610 1642 164918375893
PubMed Web of Science ®Google Scholar
Review Manager (RevMan) [Computer program]. Version 5.3CopenhagenThe Nordic Cochrane Centre, The Cochrane Collaboration2014
Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date